Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Clinical trial NCT00433745 · COMPLETED

Trial details

NCT number: NCT00433745
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome Acute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)

Start date: 2007-02-01
Primary completion: 2009-11-01
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.